SCHEMBL21954488

SCHEMBL21954488

CNc1nc(NCc2ccccc2)c2ncn(C3CCCO3)c2n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.66
▸ RAB9A P51151 1/20 0.66
▸ SMN1; SMN2 Q16637 1/20 0.66
▸ CDK1 P06493 4/20 0.54
▸ FLT3 P36888 3/20 0.54
▸ CCNE2 O96020 2/20 0.54
▸ CCNE1 P24864 2/20 0.54
▸ CDK2 P24941 2/20 0.54
▸ CCNB2 O95067 1/20 0.54
▸ CDK4 P11802 1/20 0.54
▸ CCNB1 P14635 1/20 0.54
▸ CCND1 P24385 1/20 0.54
▸ CCNB3 Q8WWL7 1/20 0.54
▸ YTHDC1 Q96MU7 1/20 0.53
▸ CTSL P07711 1/20 0.51
▸ TDP1 Q9NUW8 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ NT5E P21589 1/20 0.50
▸ CCNA2 P20248 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29659597 1.00 NPC1 (0.66) NPC1RAB9ASMN1; SMN2CDK1FLT3
SCHEMBL29659598 0.89 TDP1 (0.66) NPC1RAB9ASMN1; SMN2FLT3CCNE2
SCHEMBL20547437 0.89 TDP1 (0.66) NPC1RAB9ASMN1; SMN2FLT3CCNE2
SCHEMBL20547532 0.87 YTHDC1 (0.51) NPC1RAB9ASMN1; SMN2CDK1FLT3
SCHEMBL29659620 0.87 YTHDC1 (0.51) NPC1RAB9ASMN1; SMN2CDK1FLT3
SCHEMBL20547585 0.86 TDP1 (0.68) NPC1RAB9ASMN1; SMN2CDK1FLT3
SCHEMBL29659523 0.86 TDP1 (0.68) NPC1RAB9ASMN1; SMN2CDK1FLT3
SCHEMBL20547426 0.86 NPC1 (0.68) NPC1RAB9ASMN1; SMN2CDK1YTHDC1
SCHEMBL30410563 0.86 NPC1 (0.68) NPC1RAB9ASMN1; SMN2CDK1FLT3
SCHEMBL21954485 0.85 NPC1 (0.65) NPC1RAB9ASMN1; SMN2CDK1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643413-B2 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2023-05-09 — — US disclosed
US-20200157105-A1 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2020-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157105-A1 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS ADORA2A, UNG, P2RY6 NPC1 3725/4885RAB9A 1831/4885SMN1; SMN2 694/4885
US-11643413-B2 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders ADORA2A, UNG, P2RY6 NPC1 3725/4885RAB9A 1831/4885SMN1; SMN2 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback